Breaking News

Cmed Enters Strategic Data Management Services Pact

By Kristin Brooks | March 5, 2014

To provide data capture and management services to support early phase trials

Cmed Group, a full service CRO specializing in complex early phase trials, has entered into a strategic partnership with a top five pharmaceutical company to provide data capture and management services to support their early phase (Phase I, II, Proof of Concept) clinical trial pipeline.
 
Under the three year agreement, Cmed will provide data capture and management using its technologies, and will also collaborate on process and technology innovations to help improve and speed data visibility for critical decision making.
 
Dr. David Connelly, Cmed’s chief executive officer, said, “One of the key drivers for our client was the need for a responsive partner to provide flexible, high quality, efficient services for their fast paced, high throughput early phase pipeline. We are therefore delighted our client chose Cmed to form a strategic partnership so we can develop an already effective and efficient collaboration managing clinical data from our early phase trials into something that is truly smart and world class. We are confident that together, with our existing and emerging technologies and approaches, we can transform the setup, collection, management and review of clinical trial data.”

Related Compliance:

  • Predictive Analytics and the Future of RBM

    Rajneesh Patil, Senior Director, RBM and Analytics, QuintilesIMS||January 23, 2017
    How advances in Risk-Based Monitoring will enable a more proactive approach to identify and mitigate potential risks

  • The Growing Realm of Real-World Data

    Kristin Brooks, Contract Pharma||November 8, 2016
    PPD's Evidera acquisition aims to help clients address the growing demand for evidence from regulators and payers

  • Mastering Immunotherapy Clinical Trials: Dosing and Response

    Mastering Immunotherapy Clinical Trials: Dosing and Response

    Kristin Brooks, Contract Pharma||August 1, 2016
    Andrew Zupnick of Novella Clinical provides insights into dosing and measuring response in immunotherapy clinical trials

  • CROs and Today’s  R&D Landscape

    CROs and Today’s R&D Landscape

    Kristin Brooks, Associate Editor, Contract Pharma||November 9, 2016
    John Lewis of ACRO discusses opportunities, challenges, and the future CRO

  • Choosing Oral Formulations for First-in-man Clinical Trials

    Choosing Oral Formulations for First-in-man Clinical Trials

    Jon Sutch, Senior Manager of Formulation Development, Patheon||October 11, 2016
    Early formulations should be simple, but selecting a simple formulation isn’t as easy as it seems

  • Robust Assay Designs

    Robust Assay Designs

    Tim Wright, Editor, Contract Pharma||October 11, 2016
    Easing the transition from preclinical to clinical research